The CAR Treg construct used to transduce the Tregs included in our paper similarly showed significant IL-10 production upon activation through the CAR, which might explain the improved suppressive activity of these GD3 CAR Tregs compared to untransduced Tregs in vitro. Indeed, TCR and CAR transduction may also produce more potent and stable Tregs for in vivo, clinical use in vitiligo, and this condition holds an important advantage for investigating the superiority of antigen-specific Tregs by offering several target antigens associated with the condition (68). This evidence concerns the gene IL10 and vitiligo.